{"transactions":[{"id":694018,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-06T21:17:39.000Z","date":"2026-08-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates."}],"balance_after":27000,"derivative":{"exercise_price":17,"expiration_date":"2036-08-03","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001242882-26-000004","document":"form4-08062026_090835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000124288226000004/form4-08062026_090835.xml","form_type":"4"}},{"id":1508777,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.33,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508776,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":336755,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":7.55,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":336755},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508775,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":215000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.3,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508774,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":255000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.2,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":255000},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508773,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":270000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508772,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508771,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":208916,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":208916},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508770,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":247951,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.65,"expiration_date":"2027-03-13","underlying":"Common Stock","underlying_shares":247951},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508769,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"(Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508768,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":96000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508767,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13245,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date."}],"balance_after":96000,"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1508766,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-05-21T00:04:51.000Z","date":"2024-05-18","kind":"other","planned":false,"acquired":false,"shares":2627157,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000092","document":"wk-form4_1716249879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000092/wk-form4_1716249879.xml","form_type":"4"}},{"id":1520469,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-10T23:24:03.000Z","date":"2024-05-08","kind":"exercise","planned":false,"acquired":false,"shares":13245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":336755,"derivative":{"exercise_price":7.55,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":13245},"source":{"system":"sec-edgar","filing":"0001626199-24-000073","document":"wk-form4_1715383433.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000073/wk-form4_1715383433.xml","form_type":"4"}},{"id":1520468,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-05-10T23:24:03.000Z","date":"2024-05-08","kind":"exercise","planned":false,"acquired":true,"shares":13245,"price":7.55,"value":99999.75,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024."}],"balance_after":109245,"source":{"system":"sec-edgar","filing":"0001626199-24-000073","document":"wk-form4_1715383433.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000073/wk-form4_1715383433.xml","form_type":"4"}},{"id":1685348,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-05T23:08:42.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":240000,"derivative":{"exercise_price":18.33,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001626199-24-000025","document":"wk-form4_1704496113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000025/wk-form4_1704496113.xml","form_type":"4"}},{"id":1685347,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-01-05T23:08:42.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received grant of restricted stock units (\"RSUs\") for no consideration.  One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025  July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":96000,"source":{"system":"sec-edgar","filing":"0001626199-24-000025","document":"wk-form4_1704496113.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619924000025/wk-form4_1704496113.xml","form_type":"4"}},{"id":1697844,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Warrant (right to buy)","published_at":"2023-12-30T00:32:15.000Z","date":"2023-12-28","kind":"exercise","planned":true,"acquired":false,"shares":74441,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of a Securities Purchase Agreement, dated January 15, 2019 by and among the Issuer and the Purchasers set forth on the signature pages thereto, holder purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":12.74,"exercise_date":"2019-01-18","expiration_date":"2024-01-18","underlying":"Common Stock","underlying_shares":74441},"source":{"system":"sec-edgar","filing":"0001626199-23-000149","document":"wk-form4_1703896326.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000149/wk-form4_1703896326.xml","form_type":"4"}},{"id":1697843,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-30T00:32:15.000Z","date":"2023-12-28","kind":"exercise","planned":true,"acquired":false,"shares":1016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"100% of the shares underlying the option were fully vested as of January 20, 2021."}],"balance_after":247951,"derivative":{"exercise_price":0.65,"expiration_date":"2027-03-13","underlying":"Common Stock","underlying_shares":1016},"source":{"system":"sec-edgar","filing":"0001626199-23-000149","document":"wk-form4_1703896326.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000149/wk-form4_1703896326.xml","form_type":"4"}},{"id":1697842,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-30T00:32:15.000Z","date":"2023-12-28","kind":"tax_withholding","planned":true,"acquired":false,"shares":48264,"price":19.65,"value":948387.6,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On December 28, 2023, the warrant reported herein was net exercised in full for $12.74 per share, resulting in Issuer's withholding of 48,264 shares to pay the exercise price and issuing to the reporting person the remaining 26,177 shares"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the average closing price of Issuer's common stock for the five consecutive trading days ending on December 27, 2023 (the date immediately preceding the warrant exercise date)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2627157,"source":{"system":"sec-edgar","filing":"0001626199-23-000149","document":"wk-form4_1703896326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000149/wk-form4_1703896326.xml","form_type":"4"}},{"id":1697841,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-30T00:32:15.000Z","date":"2023-12-28","kind":"exercise","planned":true,"acquired":true,"shares":74441,"price":12.74,"value":948378.34,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2675421,"source":{"system":"sec-edgar","filing":"0001626199-23-000149","document":"wk-form4_1703896326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000149/wk-form4_1703896326.xml","form_type":"4"}},{"id":1697840,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-30T00:32:15.000Z","date":"2023-12-28","kind":"sale","planned":true,"acquired":false,"shares":1016,"price":20.0413,"value":20361.9608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000149","document":"wk-form4_1703896326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000149/wk-form4_1703896326.xml","form_type":"4"}},{"id":1697839,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-30T00:32:15.000Z","date":"2023-12-28","kind":"exercise","planned":true,"acquired":true,"shares":1016,"price":0.65,"value":660.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."}],"balance_after":1016,"source":{"system":"sec-edgar","filing":"0001626199-23-000149","document":"wk-form4_1703896326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000149/wk-form4_1703896326.xml","form_type":"4"}},{"id":1699411,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":false,"shares":29573,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the shares underlying the option were fully vested as of January 20, 2021."}],"balance_after":248967,"derivative":{"exercise_price":0.65,"expiration_date":"2027-03-13","underlying":"Common Stock","underlying_shares":29573},"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699410,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-26","kind":"exercise","planned":true,"acquired":false,"shares":22084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the shares underlying the option were fully vested as of January 20, 2021."}],"balance_after":278540,"derivative":{"exercise_price":0.65,"expiration_date":"2027-03-13","underlying":"Common Stock","underlying_shares":22084},"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699409,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-26","kind":"exercise","planned":true,"acquired":false,"shares":2402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"100% of the shares underlying the option were fully vested as of January 16, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":2402},"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699408,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-22","kind":"exercise","planned":true,"acquired":false,"shares":37825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"100% of the shares underlying the option were fully vested as of January 16, 2019."}],"balance_after":2402,"derivative":{"exercise_price":0.45,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":37825},"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699407,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-27","kind":"sale","planned":true,"acquired":false,"shares":29573,"price":20.0425,"value":592716.8525,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.37. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699406,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":true,"shares":29573,"price":0.65,"value":19222.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."}],"balance_after":29573,"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699405,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-26","kind":"sale","planned":true,"acquired":false,"shares":24486,"price":20.2245,"value":495217.107,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699404,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-26","kind":"exercise","planned":true,"acquired":true,"shares":22084,"price":0.65,"value":14354.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."}],"balance_after":24486,"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699403,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-26","kind":"exercise","planned":true,"acquired":true,"shares":2402,"price":0.45,"value":1080.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."}],"balance_after":2402,"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699402,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-22","kind":"sale","planned":true,"acquired":false,"shares":37825,"price":20.4255,"value":772594.5375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.87. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1699401,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-28T02:07:56.000Z","date":"2023-12-22","kind":"exercise","planned":true,"acquired":true,"shares":37825,"price":0.45,"value":17021.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."}],"balance_after":37825,"source":{"system":"sec-edgar","filing":"0001626199-23-000147","document":"wk-form4_1703729261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000147/wk-form4_1703729261.xml","form_type":"4"}},{"id":1702028,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-22T00:34:23.000Z","date":"2023-12-19","kind":"exercise","planned":true,"acquired":false,"shares":2402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares underlying the option were fully vested as of January 16, 2019."}],"balance_after":40227,"derivative":{"exercise_price":0.45,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":2402},"source":{"system":"sec-edgar","filing":"0001626199-23-000144","document":"wk-form4_1703205253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000144/wk-form4_1703205253.xml","form_type":"4"}},{"id":1702027,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-22T00:34:23.000Z","date":"2023-12-19","kind":"sale","planned":true,"acquired":false,"shares":2402,"price":20.0099,"value":48063.7798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000144","document":"wk-form4_1703205253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000144/wk-form4_1703205253.xml","form_type":"4"}},{"id":1702026,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-22T00:34:23.000Z","date":"2023-12-19","kind":"exercise","planned":true,"acquired":true,"shares":2402,"price":0.45,"value":1080.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023."}],"balance_after":2402,"source":{"system":"sec-edgar","filing":"0001626199-23-000144","document":"wk-form4_1703205253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000144/wk-form4_1703205253.xml","form_type":"4"}},{"id":1713921,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-13T02:02:36.000Z","date":"2023-12-12","kind":"exercise","planned":true,"acquired":false,"shares":8613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"100% of the shares underlying the option were fully vested as of January 16, 2019."}],"balance_after":42629,"derivative":{"exercise_price":0.45,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":8613},"source":{"system":"sec-edgar","filing":"0001626199-23-000134","document":"wk-form4_1702432945.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000134/wk-form4_1702432945.xml","form_type":"4"}},{"id":1713920,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-13T02:02:36.000Z","date":"2023-12-12","kind":"sale","planned":true,"acquired":false,"shares":8613,"price":17.3155,"value":149138.4015,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $17.00 to $17.56. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000134","document":"wk-form4_1702432945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000134/wk-form4_1702432945.xml","form_type":"4"}},{"id":1713919,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-13T02:02:36.000Z","date":"2023-12-12","kind":"exercise","planned":true,"acquired":true,"shares":8613,"price":0.45,"value":3875.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."}],"balance_after":8613,"source":{"system":"sec-edgar","filing":"0001626199-23-000134","document":"wk-form4_1702432945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000134/wk-form4_1702432945.xml","form_type":"4"}},{"id":1713918,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-13T02:02:36.000Z","date":"2023-12-12","kind":"sale","planned":true,"acquired":false,"shares":32450,"price":17.3155,"value":561887.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $17.00 to $17.56. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000134","document":"wk-form4_1702432945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000134/wk-form4_1702432945.xml","form_type":"4"}},{"id":1713917,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-13T02:02:36.000Z","date":"2023-12-11","kind":"sale","planned":true,"acquired":false,"shares":68870,"price":17.2648,"value":1189026.776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $17.00 to $17.75.  The price reported above reflects the weighted average sales price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":32450,"source":{"system":"sec-edgar","filing":"0001626199-23-000134","document":"wk-form4_1702432945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000134/wk-form4_1702432945.xml","form_type":"4"}},{"id":1713916,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2023-12-13T02:02:36.000Z","date":"2023-12-08","kind":"sale","planned":true,"acquired":false,"shares":8067,"price":17.0799,"value":137783.5533,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $17.00 to $17.25.  The price reported above reflects the weighted average sales price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":101320,"source":{"system":"sec-edgar","filing":"0001626199-23-000134","document":"wk-form4_1702432945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000134/wk-form4_1702432945.xml","form_type":"4"}},{"id":2062118,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-01-06T00:04:54.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":350000,"derivative":{"exercise_price":7.55,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001626199-23-000023","document":"wf-form4_167296347804493.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619923000023/wf-form4_167296347804493.xml","form_type":"4"}},{"id":2441227,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2022-01-06T23:03:14.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on the one (1)-year anniversary of January 4, 2022 (the \"Vesting Commencement Date\"), and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, such that 100% of the Shares subject to the Option will be vested and exercisable as of the four (4)-year anniversary of the Vesting Commencement Date, subject to Optionee continuing to be a Service Provider through each such date."}],"balance_after":215000,"derivative":{"exercise_price":13.3,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001626199-22-000024","document":"wf-form4_164151017636103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619922000024/wf-form4_164151017636103.xml","form_type":"4"}},{"id":2562942,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-09-21T21:16:33.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":45262,"price":10.0076,"value":452963.9912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $10.00 to $10.05.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":109387,"source":{"system":"sec-edgar","filing":"0001626199-21-000115","document":"wf-form4_163225898002703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000115/wf-form4_163225898002703.xml","form_type":"4"}},{"id":2562941,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-09-21T21:16:33.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":400000,"price":9.4,"value":3760000.0,"ownership":{"direct":false,"nature":"By Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold in a private transaction to an investor in the Issuer simultaneously with the closing of the Issuer's private placement on September 17, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2600980,"source":{"system":"sec-edgar","filing":"0001626199-21-000115","document":"wf-form4_163225898002703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000115/wf-form4_163225898002703.xml","form_type":"4"}},{"id":2565374,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-09-17T22:06:36.000Z","date":"2021-09-16","kind":"sale","acquired":false,"shares":6768,"price":10.0024,"value":67696.2432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $10.00 to $10.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":154649,"source":{"system":"sec-edgar","filing":"0001626199-21-000109","document":"wf-form4_163191637248565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000109/wf-form4_163191637248565.xml","form_type":"4"}},{"id":2565373,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-09-17T22:06:36.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":3484,"price":10,"value":34840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."}],"balance_after":161417,"source":{"system":"sec-edgar","filing":"0001626199-21-000109","document":"wf-form4_163191637248565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000109/wf-form4_163191637248565.xml","form_type":"4"}},{"id":2651461,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-06-29T21:13:43.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":3479,"price":10.0005,"value":34791.7395,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $10.00 to $10.05.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":164901,"source":{"system":"sec-edgar","filing":"0001626199-21-000087","document":"wf-form4_162500119417820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000087/wf-form4_162500119417820.xml","form_type":"4"}},{"id":2651460,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-06-29T21:13:43.000Z","date":"2021-06-25","kind":"sale","acquired":false,"shares":9473,"price":10.0143,"value":94865.4639,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $10.00 to $10.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":168380,"source":{"system":"sec-edgar","filing":"0001626199-21-000087","document":"wf-form4_162500119417820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000087/wf-form4_162500119417820.xml","form_type":"4"}},{"id":2700600,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-05-21T21:16:40.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":1221,"price":15.0006,"value":18315.7326,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $15.00 to $15.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":177853,"source":{"system":"sec-edgar","filing":"0001626199-21-000078","document":"wf-form4_162163178338161.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000078/wf-form4_162163178338161.xml","form_type":"4"}},{"id":2700599,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-05-21T21:16:40.000Z","date":"2021-05-19","kind":"sale","acquired":false,"shares":50965,"price":15.0283,"value":765917.3095,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $15.00 to $15.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":179074,"source":{"system":"sec-edgar","filing":"0001626199-21-000078","document":"wf-form4_162163178338161.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000078/wf-form4_162163178338161.xml","form_type":"4"}},{"id":2712101,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-05-14T21:17:14.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":10000,"price":11.5169,"value":115169.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $11.34 to $11.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provideupon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":230039,"source":{"system":"sec-edgar","filing":"0001626199-21-000072","document":"wf-form4_162102700497745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000072/wf-form4_162102700497745.xml","form_type":"4"}},{"id":2712100,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-05-14T21:17:14.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":10000,"price":11.6842,"value":116842.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $11.57 to $11.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provideupon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":240039,"source":{"system":"sec-edgar","filing":"0001626199-21-000072","document":"wf-form4_162102700497745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000072/wf-form4_162102700497745.xml","form_type":"4"}},{"id":2748462,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-04-15T22:09:58.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":10000,"price":10.52,"value":105200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $10.50 to $10.6450. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":250039,"source":{"system":"sec-edgar","filing":"0001626199-21-000042","document":"wf-form4_161852457474484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000042/wf-form4_161852457474484.xml","form_type":"4"}},{"id":2748461,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-04-15T22:09:58.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":10000,"price":10.0714,"value":100714.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $10.00 to $10.3075. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":260039,"source":{"system":"sec-edgar","filing":"0001626199-21-000042","document":"wf-form4_161852457474484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000042/wf-form4_161852457474484.xml","form_type":"4"}},{"id":2802796,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-03-08T22:01:30.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":10000,"price":12.9875,"value":129875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $12.85 to $13.08.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":270039,"source":{"system":"sec-edgar","filing":"0001626199-21-000033","document":"wf-form4_161524086755922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000033/wf-form4_161524086755922.xml","form_type":"4"}},{"id":2802795,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-03-08T22:01:30.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":10000,"price":13.0108,"value":130108.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $12.82 to $13.23.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":280039,"source":{"system":"sec-edgar","filing":"0001626199-21-000033","document":"wf-form4_161524086755922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000033/wf-form4_161524086755922.xml","form_type":"4"}},{"id":2881254,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-02-03T22:01:07.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":10000,"price":11.7381,"value":117381.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $11.64 to $12.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":290039,"source":{"system":"sec-edgar","filing":"0001626199-21-000031","document":"wf-form4_161238964694728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000031/wf-form4_161238964694728.xml","form_type":"4"}},{"id":2881253,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-02-03T22:01:07.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":7021,"price":13.2029,"value":92697.5609,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $13.05 to $13.38.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":300039,"source":{"system":"sec-edgar","filing":"0001626199-21-000031","document":"wf-form4_161238964694728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000031/wf-form4_161238964694728.xml","form_type":"4"}},{"id":2881252,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-02-03T22:01:07.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":2979,"price":12.0738,"value":35967.8502,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $11.66 to $12.515.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":307060,"source":{"system":"sec-edgar","filing":"0001626199-21-000031","document":"wf-form4_161238964694728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000031/wf-form4_161238964694728.xml","form_type":"4"}},{"id":2915090,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2021-01-07T01:03:46.000Z","date":"2021-01-05","kind":"grant","acquired":true,"shares":255000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":255000,"derivative":{"exercise_price":13.2,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":255000},"source":{"system":"sec-edgar","filing":"0001626199-21-000028","document":"wf-form4_160998141101682.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000028/wf-form4_160998141101682.xml","form_type":"4"}},{"id":2925303,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2021-01-05T01:37:44.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":11123,"price":12.6,"value":140149.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":310039,"source":{"system":"sec-edgar","filing":"0001626199-21-000004","document":"wf-form4_160981064946872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000162619921000004/wf-form4_160981064946872.xml","form_type":"4"}},{"id":2934427,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2020-12-22T22:30:12.000Z","date":"2020-12-22","kind":"other","acquired":true,"shares":260528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Acquisition by the Reporting Person pursuant to the Distribution."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Acquisition by the Reporting Person pursuant to the Distribution."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 33,785 RSUs that represent contingent rights to receive 33,785 shares of the Issuer's common stock upon settlement."}],"balance_after":321162,"source":{"system":"sec-edgar","filing":"0000899243-20-034854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924320034854/doc4.xml","form_type":"4"}},{"id":2934426,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2020-12-22T22:30:12.000Z","date":"2020-12-22","kind":"other","acquired":false,"shares":993801,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Alpine ImmunoSciences, L.P. distributed these shares to its limited partners on a pro rata basis for no consideration (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Alpine ImmunoSciences, L.P. distributed these shares to its limited partners on a pro rata basis for no consideration (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P.  Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC.  Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P.  By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3000980,"source":{"system":"sec-edgar","filing":"0000899243-20-034854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924320034854/doc4.xml","form_type":"4"}},{"id":3095045,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2020-07-01T23:24:30.000Z","date":"2020-06-30","kind":"tax_withholding","acquired":false,"shares":8227,"price":9.71,"value":79884.17,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units.  Each restricted stock unit represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each restricted stock unit."}],"balance_after":60634,"source":{"system":"sec-edgar","filing":"0000899243-20-018173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924320018173/doc4.xml","form_type":"4"}},{"id":3301179,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-27T23:00:23.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":270000,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0000899243-20-002067","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924320002067/doc4.xml","form_type":"4"}},{"id":3301178,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2020-01-27T23:00:23.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":67569,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received a grant of restricted stock units (\"RSUs\") pursuant to the 2018 Equity Incentive Plan for no consideration.  The RSUs were granted in lieu of cash incentive compensation achieved pursuant to the terms of the Company's Executive Incentive Compensation Plan.  Fifty percent (50%) of the RSUs will vest on June 30, 2020 and fifty percent (50%) of the RSUs will vest on December 31, 2020, subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":68861,"source":{"system":"sec-edgar","filing":"0000899243-20-002067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924320002067/doc4.xml","form_type":"4"}},{"id":3301177,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2020-01-27T23:00:23.000Z","date":"2019-12-23","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1292,"source":{"system":"sec-edgar","filing":"0000899243-20-002067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924320002067/doc4.xml","form_type":"4"}},{"id":3301176,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2020-01-27T23:00:23.000Z","date":"2019-12-11","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6292,"source":{"system":"sec-edgar","filing":"0000899243-20-002067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924320002067/doc4.xml","form_type":"4"}},{"id":3667850,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T21:30:21.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of February 6, 2019 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month  thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":200000,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-19-003032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924319003032/doc4.xml","form_type":"4"}},{"id":3690541,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Warrant (right to buy)","published_at":"2019-01-23T01:44:48.000Z","date":"2019-01-18","kind":"purchase","acquired":true,"shares":74441,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":74441,"derivative":{"exercise_price":12.74,"exercise_date":"2019-01-18","expiration_date":"2024-01-18","underlying":"Common Stock","underlying_shares":74441},"source":{"system":"sec-edgar","filing":"0000899243-19-001662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924319001662/doc4.xml","form_type":"4"}},{"id":3690540,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2019-01-23T01:44:48.000Z","date":"2018-05-21","kind":"gift","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11292,"source":{"system":"sec-edgar","filing":"0000899243-19-001662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924319001662/doc4.xml","form_type":"4"}},{"id":3690539,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2019-01-23T01:44:48.000Z","date":"2018-05-15","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17292,"source":{"system":"sec-edgar","filing":"0000899243-19-001662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924319001662/doc4.xml","form_type":"4"}},{"id":3690538,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2019-01-23T01:44:48.000Z","date":"2018-05-14","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20292,"source":{"system":"sec-edgar","filing":"0000899243-19-001662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924319001662/doc4.xml","form_type":"4"}},{"id":3690537,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2019-01-23T01:44:48.000Z","date":"2019-01-18","kind":"purchase","acquired":true,"shares":190875,"price":5.37,"value":1024998.75,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3994781,"source":{"system":"sec-edgar","filing":"0000899243-19-001662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924319001662/doc4.xml","form_type":"4"}},{"id":4107165,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-01-04T22:21:09.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option become vested and exercisable on January 2, 2019 and 1/36th of the remaining shares subject to the option shall vest monthly thereafter."}],"balance_after":70000,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-18-000495","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924318000495/doc4.xml","form_type":"4"}},{"id":4250849,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"grant","acquired":true,"shares":208916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option vests 25% on January 20, 2018, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."}],"balance_after":208916,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":208916},"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}},{"id":4250848,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"grant","acquired":true,"shares":300624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option vests 25% on January 20, 2018, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."}],"balance_after":300624,"derivative":{"exercise_price":0.65,"expiration_date":"2027-03-13","underlying":"Common Stock","underlying_shares":300624},"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}},{"id":4250847,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"grant","acquired":true,"shares":51242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Reporting Person was initially granted an option to acquire 300,000 shares, 150,000 shares of which vested on May 16, 2016, and the remaining shares vested or vest in 32 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."}],"balance_after":51242,"derivative":{"exercise_price":0.45,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":51242},"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}},{"id":4250846,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":3803906,"ownership":{"direct":false,"nature":"Alpine Immunosciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine Immunosciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine Immunosciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine Immunosciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3803906,"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}},{"id":4250845,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"grant","acquired":true,"shares":23292,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."}],"balance_after":23292,"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}},{"id":4250844,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":24845,"ownership":{"direct":false,"nature":"By The Mitch & Dawn Gold Irrevocable Trust fbo Simon P. Gold"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bradley Hurwitz serves as the trustee for these trusts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":24845,"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}},{"id":4250843,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":24845,"ownership":{"direct":false,"nature":"By The Mitch & Dawn Gold Irrevocable Trust fbo Noah M. Gold"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bradley Hurwitz serves as the trustee for these trusts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":24845,"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}},{"id":4250842,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25804,"kind":"person","name":"GOLD MITCHELL","position":1,"cik":"0001242882","reported_name":"GOLD MITCHELL","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman and CEO"}}],"security":"Common Stock","published_at":"2017-07-26T21:13:05.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":24845,"ownership":{"direct":false,"nature":"By The Mitch & Dawn Gold Irrevocable Trust fbo Aidan J. Gold"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bradley Hurwitz serves as the trustee for these trusts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":24845,"source":{"system":"sec-edgar","filing":"0000899243-17-019069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242882/000089924317019069/doc4.xml","form_type":"4"}}]}